A Phase 1 interventional study of CP-690,550 (tasocitinib) in Rheumatoid Arthritis, sponsored by Pfizer. Completed at 11 sites in 2 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-23.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing tofacitinib in Arthritis, Rheumatoid — 9 open to participants now, 9 under way, 1 of them phase 3. tofacitinib · Arthritis, Rheumatoid.
Among the 43 studies testing tofacitinib in Arthritis, Rheumatoid, this one is the 34th largest by enrollment, is one of 2 that started in 2011, is one of 6 in phase 1, and was the 18th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →9 of the 43 studies testing tofacitinib in Arthritis, Rheumatoid are open now, in 6 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Shaikh Zayed Hospital, Lahore · Sites in Pakistan
Ages 50–85
University Hospital, Toulouse · Sites in France
Ages 18–65
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–65
Marie Hudson, MD · Sites in Canada
Ages 18+
By country, each count listing its studies:
tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 69 is below the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 170 across the 43 interventional studies. Of the 30 that completed or were terminated, 23 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 43 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
152 studies in Arthritis, Rheumatoid by Pfizer: 2 open now, 2 under way, none of them phase 3. Of 149 finished, 105 (70%) have results posted.
Among the 152 studies in Arthritis, Rheumatoid by Pfizer, this one is the 61st largest by enrollment of the 86 interventional ones that give a count, is one of 9 that started in 2011, is one of 23 in phase 1, and was the 86th registered.
Pfizer’s Arthritis, Rheumatoid studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 43 studies testing tofacitinib in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 152 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of study is to explore the effect of CP-690,550 (tasocitinib) on cholesterol metabolism in patients with active rheumatoid arthritis (RA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: CP-690,550 (tasocitinib)
No intervention
CP-690,550 (tasocitinib) dosed at 10 mg BID for 6 weeks in patients with active rheumatoid arthritis
High-density Lipoprotein Cholesterol (HDL-C) Concentration at Baseline
Blood level of HDL-C was measured following a 12-hours fasting.
Time frame: Baseline
High-density Lipoprotein Cholesterol (HDL-C) Concentration at Week 6
Blood level of HDL-C was measured following a 12-hours fasting.
Time frame: Week 6
Cholesterol Ester Production Rate at Baseline
Cholesterol ester production rate was calculated using a 3-pool model with a simulation, analysis and modeling (SAAM II) program.
Time frame: Baseline
Cholesterol Ester Production Rate at Week 6
Cholesterol ester production rate was calculated using a 3-pool model with a simulation, analysis and modeling (SAAM II) program.
Time frame: Week 6
Low-density Lipoprotein Cholesterol (LDL-C) and Total Cholesterol Concentration
Blood level of LDL-C and total cholesterol (TC) was measured following a 12-hours fasting.
Time frame: Baseline, Week 6
Cholesterol Ester Fractional Catabolic Rate
Cholesterol ester fractional catabolic rate were calculated using a 3-pool model with a simulation, analysis and modeling (SAAM II) program. Fractional catabolic rate was the percentage of cholesterol ester which was replaced, transferred or lost per unit of time.
Time frame: Baseline, Week 6
Low-density Lipoprotein Associated With Apolipoprotein B (LDL-apoB) Production Rate
LDL-apoB production rate were calculated using a 3-pool model with a simulation, analysis and modeling (SAAM II) program.
Time frame: Baseline, Week 6
Low-density Lipoprotein Associated With Apolipoprotein B (LDL-apoB) Fractional Catabolic Rate
Fractional catabolic rate for LDL ApoB were calculated using the 13 carbon (13C) isotopic enrichment of very low density lipoprotein (VLDL) as the limiting value. Isotope 13C in plasma was measured using Gas Chromatography-Combustion-Isotope Ratio Mass Spectrometry (GC-C-IRMS).
Time frame: Baseline, Week 6
High-density Lipoprotein Associated With Apolipoprotein A1 (HDL-apoA1) Production Rate
HDL-apoA1 production rate were calculated using a 3-pool model with a simulation, analysis and modeling (SAAM II) program.
Time frame: Baseline, Week 6
High-density Lipoprotein Associated With Apolipoprotein A1 (HDL-apoA1) Fractional Catabolic Rate
Fractional catabolic rate for HDL-apoA1 were calculated using the 13C isotopic enrichment of VLDL as the limiting value. Isotope 13C in plasma was measured using GC-C-IRMS.
Time frame: Baseline, Week 6
Cholesterol Efflux Rate
Cholesterol efflux rate was measured using isotope dilution method in which rate of appearance of isotope 13C-free cholesterol in plasma representing whole body efflux from tissues was assessed. Isotope 13C in plasma was measured using GC-C-IRMS.
Time frame: Baseline, Week 6
| Milestone | Rheumatoid Arthritis Cohort | Healthy Volunteers Cohort |
|---|---|---|
| Started | 36 | 33 |
| Completed | 36 | 33 |
| Not completed | 0 | 0 |
| Milestone | Rheumatoid Arthritis Cohort | Healthy Volunteers Cohort |
|---|---|---|
| Started | 36 | 0 |
| Completed | 36 | 0 |
| Not completed | 0 | 0 |
Blood level of HDL-C was measured following a 12-hours fasting.
| milligram per deciliter (mg/dL) | Rheumatoid Arthritis Cohort | Healthy Volunteer Cohort |
|---|---|---|
| High-density Lipoprotein Cholesterol (HDL-C) Concentration at Baseline | 54.30 ± 12.52 | 63.43 ± 16.89 |
Blood level of HDL-C was measured following a 12-hours fasting.
| mg/dL | Rheumatoid Arthritis Cohort |
|---|---|
| High-density Lipoprotein Cholesterol (HDL-C) Concentration at Week 6 | 62.34 ± 15.24 |
Cholesterol ester production rate was calculated using a 3-pool model with a simulation, analysis and modeling (SAAM II) program.
| (mg per kilogram) per hour ([mg/kg]/hr) | Rheumatoid Arthritis Cohort | Healthy Volunteer Cohort |
|---|---|---|
| Cholesterol Ester Production Rate at Baseline | 1.09 ± 0.24 | 1.11 ± 0.26 |
Cholesterol ester production rate was calculated using a 3-pool model with a simulation, analysis and modeling (SAAM II) program.
| (mg/kg)/hr | Rheumatoid Arthritis Cohort |
|---|---|
| Cholesterol Ester Production Rate at Week 6 | 1.12 ± 0.24 |
Blood level of LDL-C and total cholesterol (TC) was measured following a 12-hours fasting.
| mg/dL | Rheumatoid Arthritis Cohort | Healthy Volunteer Cohort |
|---|---|---|
| Baseline: LDL-C | 124.61 ± 28.55 | 144.88 ± 36.36 |
| Baseline: TC | 193.79 ± 32.56 | 221.57 ± 42.12 |
| Week 6: LDL-C | 142.68 ± 39.02 | NA ± NA |
| Week 6: TC | 219.83 ± 41.33 | NA ± NA |
Cholesterol ester fractional catabolic rate were calculated using a 3-pool model with a simulation, analysis and modeling (SAAM II) program. Fractional catabolic rate was the percentage of cholesterol ester which was replaced, transferred or lost per unit of time.
| percentage ester per hour (%/hr) | Rheumatoid Arthritis Cohort | Healthy Volunteer Cohort |
|---|---|---|
| Baseline | 2.43 ± 0.39 | 2.17 ± 0.36 |
| Week 6 | 2.23 ± 0.31 | NA ± NA |
LDL-apoB production rate were calculated using a 3-pool model with a simulation, analysis and modeling (SAAM II) program.
| (mg/kg)/hr | Rheumatoid Arthritis Cohort | Healthy Volunteer Cohort |
|---|---|---|
| Baseline | 0.49 ± 0.12 | 0.50 ± 0.13 |
| Week 6 | 0.52 ± 0.12 | NA ± NA |
Fractional catabolic rate for LDL ApoB were calculated using the 13 carbon (13C) isotopic enrichment of very low density lipoprotein (VLDL) as the limiting value. Isotope 13C in plasma was measured using Gas Chromatography-Combustion-Isotope Ratio Mass Spectrometry (GC-C-IRMS).
| %/hr | Rheumatoid Arthritis Cohort | Healthy Volunteer Cohort |
|---|---|---|
| Baseline | 1.61 ± 0.37 | 1.50 ± 0.35 |
| Week 6 | 1.57 ± 0.41 | NA ± NA |
HDL-apoA1 production rate were calculated using a 3-pool model with a simulation, analysis and modeling (SAAM II) program.
| mg/kg/hr | Rheumatoid Arthritis Cohort | Healthy Volunteer Cohort |
|---|---|---|
| Baseline | 0.57 ± 0.11 | 0.59 ± 0.16 |
| Week 6 | 0.65 ± 0.15 | NA ± NA |
Fractional catabolic rate for HDL-apoA1 were calculated using the 13C isotopic enrichment of VLDL as the limiting value. Isotope 13C in plasma was measured using GC-C-IRMS.
| %/hr | Rheumatoid Arthritis Cohort | Healthy Volunteer Cohort |
|---|---|---|
| Baseline | 1.08 ± 0.22 | 1.02 ± 0.22 |
| Week 6 | 1.11 ± 0.28 | NA ± NA |
Cholesterol efflux rate was measured using isotope dilution method in which rate of appearance of isotope 13C-free cholesterol in plasma representing whole body efflux from tissues was assessed. Isotope 13C in plasma was measured using GC-C-IRMS.
| (mg/kg)/hr | Rheumatoid Arthritis Cohort | Healthy Volunteer Cohort |
|---|---|---|
| Baseline | 4.02 ± 0.96 | 4.35 ± 1.53 |
| Week 6 | 4.04 ± 1.08 | NA ± NA |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rheumatoid Arthritis Cohort | — | 0/36 (0%) | 19/36 (52.8%) |
| Healthy Volunteer Cohort | — | 0/33 (0%) | 6/33 (18.2%) |
| Event | Rheumatoid Arthritis Cohort | Healthy Volunteer Cohort |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 7/36 | 0/33 |
| HeadacheNervous system disorders | 4/36 | 4/33 |
| Urinary tract infectionInfections and infestations | 3/36 | 0/33 |
| Abdominal distensionGastrointestinal disorders | 2/36 | 0/33 |
| DyspepsiaGastrointestinal disorders | 2/36 | 0/33 |
| Oedema peripheralGeneral disorders | 1/36 | 1/33 |
| MigraineNervous system disorders | 1/36 | 1/33 |
| Abdominal pain upperGastrointestinal disorders | 1/36 | 0/33 |
| DiarrhoeaGastrointestinal disorders | 1/36 | 0/33 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/36 | 0/33 |
| Age, Customized(participants) | Rheumatoid Arthritis Cohort | Healthy Volunteers Cohort | Total |
|---|---|---|---|
| 18 to 44 years | 9 | 7 | 16 |
| 45 to 64 years | 25 | 25 | 50 |
| Greater than or equal to (>=) 65 years | 2 | 1 | 3 |
| Sex: Female, Male(Participants) | Rheumatoid Arthritis Cohort | Healthy Volunteers Cohort | Total |
|---|---|---|---|
| Female | 30 | 28 | 58 |
| Male | 6 | 5 | 11 |
The record gives a start of May 2011, a primary completion of Jan 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib